Please use this identifier to cite or link to this item:
Title: Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial.
Authors: Bailey, T S
Takács, R
Tinahones, F J
Rao, P V
Tsoukas, G M
Thomsen, A B
Kaltoft, M S
Maislos, M
Keywords: GLP-1 receptor agonist;liraglutide;sitagliptin;type 2 diabetes
metadata.dc.subject.mesh: Adult
Aged, 80 and over
Blood Glucose
Body Weight
Diabetes Mellitus, Type 2
Double-Blind Method
Drug Substitution
Drug Therapy, Combination
Glycated Hemoglobin
Hypoglycemic Agents
Middle Aged
North America
Sitagliptin Phosphate
Treatment Outcome
Issue Date: 14-Sep-2016
Abstract: To confirm superiority on glycaemic control by switching from sitagliptin to liraglutide 1.8 mg/d versus continued sitagliptin. A randomized, multicentre, double-blind, double-dummy, active-controlled trial across 86 office- or hospital-based sites in North America, Europe and Asia. Subjects with type 2 diabetes who had inadequate glycaemic control (glycated haemoglobin [HbA1c] 7.5-9.5% on sitagliptin (100 mg/d) and metformin (≥1500 mg daily) for ≥90 days were randomized to either switch to liraglutide (n = 203) or continue sitagliptin (n = 204), both with metformin. The primary endpoint was change in HbA1c from baseline to week 26. Change in body weight was a confirmatory secondary endpoint. Greater reduction in mean HbA1c was achieved with liraglutide than with continued sitagliptin [-1.14% vs. -0.54%; estimated mean treatment difference (ETD): -0.61% (95% CI -0.82 to -0.40; p  Subjects insufficiently controlled with sitagliptin who switch to liraglutide can obtain clinically relevant reductions in glycaemia and body weight, without compromising safety. A switch from sitagliptin to liraglutide provides an option for improved management of type 2 diabetes while still allowing patients to remain on dual therapy.
metadata.dc.identifier.doi: 10.1111/dom.12736
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC5129465.pdf949,12 kBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons